Journal Mobile Options
Table of Contents
Vol. 67, No. 3, 2005
Issue release date: 2005
ORL 2005;67:148–153

Role of Leukotriene Inhibitors in the Postoperative Management of Nasal Polyps

Mostafa B.E. · Hay H.A. · Mohammed H.E. · Yamani M.
Departments of aOtorhinolaryngology Ain-Shams and bBenha Universities, Cairo, Egypt

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


This was a prospective double blind comparative study on 40 patients. It compared the effects of the leukotriene receptor antagonist montelukast and beclomethasone nasal spray on the post-operative course of patients with sinonasal polyps. All patients underwent endoscopic sphenoethmoidectomy and were randomized post-operatively into two groups. Group I: 20 patients (9 females and 11 males) age 17 to 67 (32.4 ± 9.5 years), receiving 10 mg montelukast orally daily and Group II: 20 patients (6 females and 14 males) age 17 years to 57 years (33.5 ± 11.9 years), receiving 400 ug beclomethasone local sprays daily. All patients were followed up for 1 year and a symptom score was recorded throughout this period. There was a significant reduction in symptom scores in both groups throughout the study period. In the montelukast group improvement was more marked in itching, post-nasal discharge and headache. The control of sneezing and rhinorrhea was comparable in both groups with a marginal advantage of montelukast. Steroids had a more marked effect on smell disturbances and obstruction. There was no difference in the recurrence rate or in the need for rescue medications between both groups. Both drugs seem to have a complementary action and further studies are needed to determine which patients should receive which treatment.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Dirienzo L, Artuso A, Cerqua N: Antileukotrienes in the prevention of postoperative recurrence of nasal polyposis in ASA syndrome. Acta Otorhinolaryngol Ital 2000;20:336–342.
  2. Fisher AR, Rosenberg MA, Lily CM: Direct evidence for the role of the mast cell in the nasal response to aspirin in aspirin-insensitive asthma. J Allergy Clin Immunol 1994;94:1046–1056.
  3. Hedman J, Kaprio J, Poussa I: Prevalence of asthma, aspirin intolerance, nasal polyposis, and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol 1999;28:717–722.
  4. Kramer MF, Rasp G: Nasal polyposis: Eosinophils and interleukin-5. Allergy 1999;54:669–680.
  5. Kurowski M, Kuna P, Gorski P: Montelukast plus cetirizine in the prophylactic treatment of seasonal allergic rhinitis: Influence on clinical symptoms and nasal allergic inflammation. Allergy 2004;59:280–288.
  6. Larsen K: The clinical relationship of nasal polyps to asthma.Allergy Asthma Proc 1996;17:243–24.
  7. Larsen PL,Tos M: A long term follow-up study of nasal polyp patients after simple polypectomies.Eur Arch Oto-Rhino-Laryngol 1997;1:s85–s88.
  8. Lee CH, Lee KS, Rhee CS: Distribution of RANTES and interleukin 5 in allergic nasal mucosa and nasal polyps. Ann Otol Rhinol Laryngol 1999;108:594–598.
  9. Meltzer EO, Malmstrom K, Lu S: Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trial. J Allergy Clin Immunol 2000;105:914–922.

    External Resources

  10. Morinaka S, Nakamura H: Inflammatory cells in nasal mucosa and nasal polyps. Auris Nasus Larynx 2000;27:59–64.
  11. Mostafa BE, El Fiky L, Sallam FA: Simple clinical system for the prediction of recurrence of nasal polyps. Auris Nasus Larynx 1999;26:165–168.
  12. Mygind N, Dahl R, Bachert C: Nasal polyposis, eosinophils dominated inflammation and allergy. Thorax 2000;55(suppl):s59–s83.
  13. Naclerio RM, Baroody FM, Togias AG: The role of leukotrienes in allergic rhinitis: A review. J Rev Respir Dis 1991;143:S91–S95.
  14. Naclerio RM, Mackay I: Guidelines for the management of nasal polyposis; in Mygind N, Lildholdt T (eds): Nasal Polyposis: An Inflammatory Disease and Its Treatment. Copenhagen, Munksgaard, 1997, pp 177–180.
  15. Nayak AS, Philip G, Lu S: Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: A multi-center, randomized, double-blind placebo-controlled trial performed in the Fall. Ann Allergy Asthma Immunol 2002;88:592–600.
  16. Parnes SM, Chuma AV: Acute effects of antileukotrienes on sinonasal polyposis and sinusitis. Ear Nose Throat J 2000;79:18–20.
  17. Philip G, Malmstrom K, Hampel FC: Montelukast for treating seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled trial per formed in the Spring. Clin Exp Allergy 2002;32:1020–1028.
  18. Pullerits T, Praks L, Skoogh BE, Ani R, Lotvall J: Randomized placebo-controlled study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergic rhinitis. Am J Respir Crit Care Med 1999;159:1814–1818.
  19. Radenne F, Lamblin C, Vandezande LM: Quality of life in nasal polyposis. J Allergy Clin Immunol 1999;104:79–84.
  20. Ragab S, Parikh A, Darby YC, Scadding OK: An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma. Clin Exp Allergy 2001;31:1385–1391.
  21. Rugina M, Serrano E, Klossek JM, Crampette L, Stoll D, Bebear JP: Epidemiological and clinical aspects of nasal polyposis in France: The ORLI group experience. Rhinology 2002;40:75–79.
  22. Ulualp SO, Sterman GM, Toohill R: Antileukotriene therapy for the relief of sinus symptoms in aspirin triad disease. Ear Nose Throat 1999;78:604–606.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50